Immuneering appoints Matushansky as Chief Medical Officer

Immuneering (IMRX) announced that Igor Matushansky, MD, PhD, has joined the company as Chief Medical Officer. In this role, he will direct Immuneering’s clinical activities, providing medical and operational leadership for the company’s development programs including an ongoing Phase 2a study of lead program IMM-1-104 in pancreatic cancer, lung cancer, and melanoma, and plans to initiate a pivotal Phase 3 clinical trial in pancreatic cancer.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue